<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00165880</url>
  </required_header>
  <id_info>
    <org_study_id>E7070-E044-213</org_study_id>
    <secondary_id>2004-000774-31</secondary_id>
    <nct_id>NCT00165880</nct_id>
  </id_info>
  <brief_title>An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine</brief_title>
  <official_title>An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Metastatic Breast Cancer Patients Following Prior Anthracycline and Taxane Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      The overall purpose of this study is to compare the efficacy, safety and tolerability of
      indisulam in combination with capecitabine (IC) versus capecitabine (C) monotherapy in
      patients with metastatic breast cancer who have previously been treated with an anthracycline
      and a taxane.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study was stopped prematurely due to lack of efficacy.
  </why_stopped>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor measurements to be done by CT/MRI or photography in accordance with the RECIST criteria and radiography protocol provided. Six month and median overall survival, pain and analgesia score.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical examination, adverse events, laboratory screens and electrocardiograms. Also, independent radiological review using RECIST criteria.</measure>
  </secondary_outcome>
  <enrollment type="Actual">62</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E7070</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulant female patients with metastatic breast cancer who have been treated
             previously with an anthracycline and a taxane will be enrolled.

          -  Patients must fulfill the following criteria to be included in the study:

          -  Histologically or cytologically confirmed breast cancer with at least one ---
             metastatic uni-dimensionally measurable lesion according to RECIST criteria (the
             following do not qualify as measurable lesions: bone, leptomeningeal disease, ascites,
             pleural/pericardial effusion, lymphangitis cutis/pulmonis, abdominal masses that are
             not confirmed and followed by imaging techniques, and cystic lesions).

          -  Prior treatment with an anthracycline and a taxane.

          -  All previous treatment (including surgery and radiotherapy) must have been completed
             at least 4 weeks prior to study entry and any acute toxicities must have resolved.

          -  Age &gt;= 18 years.

          -  Karnofsky performance status of &gt;= 70%.

          -  Written informed consent to participate in the study.

        Exclusion Criteria:

        Patients with the following characteristics will not be included in the study:

          -  Previously received greater than two prior chemotherapy regimens for metastatic breast
             cancer.

          -  Previously received greater than three prior chemotherapy regimens in total (including
             neo-adjuvant and adjuvant regimens) for breast cancer.

          -  Primary diagnosis of inflammatory breast cancer, confirmed by histology or cytology.

          -  Untreated brain metastases (patients who have been treated for CNS metastases must be
             asymptomatic and radiologically stable for 3 months prior to entry). Patients must not
             have clinical symptoms from brain metastases and must not be taking corticosteroids
             for the treatment of brain metastases. Patients must not have leptomeningeal
             metastases.

          -  Concurrent or previous malignancy of a different tumor type within five years of
             starting the study except for adequately treated non-melanoma skin cancer or cervical
             intraepithelial neoplasia.

          -  Any of the following laboratory parameters:

               1. hemoglobin &lt;10 g/dl;

               2. neutrophils &lt;1.5 x 109/L;

               3. platelets &lt;100 x 109/L;

               4. serum bilirubin &gt;25 Âµmol/l (1.5 mg/dl);

               5. other liver parameters &gt;2.5 x upper normal limit (ULN) (&gt; 5 x upper normal limit
                  in the presence of hepatic metastases);

               6. serum creatinine &gt;1.5 x ULN;

               7. serum calcium (corrected for albumin) &gt;=11.5 mg/dl.

          -  Uncontrolled infections.

          -  Clinically significant cardiac impairment or unstable ischemic heart disease including
             a myocardial infarction within six months of study start.

          -  Malabsorption syndrome or other condition which may affect drug absorption.

          -  History of hypersensitivity to sulfonamides.

          -  Prior severe or unexpected reaction to fluoropyrimidine therapy (which may be
             explained by dihydropyrimidine dehydrogenase deficiency or hypersensitivity to
             5-fluorouracil).

          -  Any treatment with investigational drugs within 30 days before the start of the study.

          -  Pregnancy or lactation (all women of childbearing potential must have a negative
             pregnancy test before inclusion in the study; post-menopausal women must be
             amenorrheic for at least 12 months). Fertile patients must use adequate contraceptive
             protection.

          -  History of alcoholism, drug addiction, or any psychiatric or psychological condition
             which, in the opinion of the investigator, would impair study compliance.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jantien Wanders</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite Universitatsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>D-12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stadt Kliniken Frankfurt-Hochst</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IORC Gmbh</name>
      <address>
        <city>Hamburg</city>
        <zip>D-22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Mainz</city>
        <zip>D-55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum fur Innere Medizin Hamatologie / Onkologie</name>
      <address>
        <city>Stuttgart</city>
        <zip>D-70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Ruiniti</name>
      <address>
        <city>Bergamo</city>
        <zip>I-24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Maria Annunzialata</name>
      <address>
        <city>Firenze</city>
        <zip>I-50011</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Morgagni-Pierantoni</name>
      <address>
        <city>Forli</city>
        <zip>I-47100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IST Istituto nazionale per la Ricerca</name>
      <address>
        <city>Genova</city>
        <zip>I-16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palilinico Universitano</name>
      <address>
        <city>Palermo</city>
        <zip>I-90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>I-56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Arciospedate S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>I-42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Filippo Neri</name>
      <address>
        <city>Roma</city>
        <zip>I-00135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk Regional Clinical Oncology Center</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk Regional Oncology Center</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krasnodar City Oncology Center</name>
      <address>
        <city>Krasnodar</city>
        <zip>350040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leningrad Regional Oncology Center</name>
      <address>
        <city>Kuzmolovo</city>
        <zip>188663</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hertzen Research Institute of Oncology</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semashko Central Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov Oncology Research Institute</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344037</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petrov Research Institute of Oncology</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universiatio de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>I-19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Regional de Galicia</name>
      <address>
        <city>La Coruna</city>
        <zip>E-15009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Unicersaitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>E-28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Anderson Internacional</name>
      <address>
        <city>Madrid</city>
        <zip>E-28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico U. Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>E-29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>E-50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>I-19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cookridge Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS16 6QB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital NHS Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4GJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre</name>
      <address>
        <city>Northwood</city>
        <zip>HA1 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South West Wales Cancer Institute</name>
      <address>
        <city>Swansea</city>
        <zip>SA2 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>June 30, 2014</last_update_submitted>
  <last_update_submitted_qc>June 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2014</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

